Once per browser per day · Korea time · Counts may lag up to 5 minutes
STRUCTUREMOA / MOLECULAR ATLAS
Read the structure.
Discover the difference.
A sourced molecular atlas for oncology, neuroscience and drug chemistry. Compare actual structures, follow their origins, and explore what makes each molecule different.
Same family. Independent molecular identities.
EXPLORE THE ATLAS
Find your field of interest
KRAS G12C inhibitor chemical landscape
5 sourced entries · Open molecular map
EGFR tyrosine kinase inhibitor series
6 sourced entries · Open molecular map
MMAE (auristatin) payload family
3 sourced entries · Open molecular map
DM1 / maytansinoid payload family
3 sourced entries · Open molecular map
Exatecan / DXd (TOP1 inhibitor) payload family
5 sourced entries · Open molecular map
SN-38 / irinotecan (TOP1) small-molecule series
4 sourced entries · Open molecular map
A CLOSER LOOK
From a molecule to a clearer comparison
A family is a starting point. The evidence behind each structure is what makes the comparison useful.
READING THE STRUCTURES
Notes for a better comparison
KRAS comparisons: molecular structure and binding state
Read sotorasib and adagrasib independently, and distinguish daraxonrasib’s RAS(ON) approach.
02 / STRUCTURE NOTEGefitinib, erlotinib and osimertinib: structures and binding evidence
A worked EGFR comparison that separates molecular observations from experimental binding evidence.
03 / STRUCTURE NOTEAn ADC payload drawing is not the whole ADC
Compare MMAE and DM1 at the molecular level, then keep antibody, linker and conjugation information separate.
OUR EDITORIAL STANDARD
Every structure needs a source.
Each public molecular entry is independently sourced. Internal mock molecules and inherited structures are excluded. Structural similarity does not establish potency, safety or clinical benefit.
How we review the catalog